Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Drugs R D[TA])
1,118 results
  • Novel Strategies for the Treatment of COVID-19. [Randomized Controlled Trial]
    Drugs R D. 2022 Dec; 22(4):257-262.McCarthy MW
  • On 4 September, 2020, the US National Institutes of Health launched a new clinical trial, "A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults with COVID-19." This open-label, placebo-controlled, multicenter, adaptive platform study was designed to evaluate therapeutic options for patients hosp…
  • Antiplatelets Versus Anticoagulation in Cervical Artery Dissection: A Systematic Review and Meta-analysis of 2064 Patients. [Meta-Analysis]
    Drugs R D. 2022 Sep; 22(3):187-203.Hagrass AI, Almaghary BK, … Doheim MF
  • CONCLUSIONS: Our study did not show a considerable difference between the two groups, as all outcomes showed non-significant differences between them, except for primary ischaemic stroke (RCTs) and complete recanalization (observational studies), which showed a significant favour of AC over AP. Even though primary ischaemic stroke is an important outcome, several crucial points that could affect these results should be paid attention to. These include the incomplete adjustment for the confounding effect of AP-AC doses, frequencies, administration compliance, and others. We recommend more well-designed studies to assess if unnecessary anticoagulation can be avoided in CeAD.
  • Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9. [Journal Article]
    Drugs R D. 2022 Jun; 22(2):165-173.Kottom TJ, Schaefbauer K, … Limper AH
  • CONCLUSIONS: In our initial general safety and toxicology assessments, BRD5529 displayed no inherent safety concerns in the analyzed parameters. These data support broader in vivo testing of the inhibitor as a timed adjunct therapy to the deleterious proinflammatory host immune response often associated with anti-Pneumocystis therapy.
  • Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections. [Review]
    Drugs R D. 2022 Jun; 22(2):113-117.McCarthy MW
  • Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, eradicates biofilms, and acts synergistically with other antibiotics. Combinations including exebacas…
New Search Next